Review
Version 1
Preserved in Portico This version is not peer-reviewed
Retinoid X Receptor Antagonists
Version 1
: Received: 12 June 2018 / Approved: 13 June 2018 / Online: 13 June 2018 (10:45:58 CEST)
A peer-reviewed article of this Preprint also exists.
Watanabe, M.; Kakuta, H. Retinoid X Receptor Antagonists. Int. J. Mol. Sci. 2018, 19, 2354. Watanabe, M.; Kakuta, H. Retinoid X Receptor Antagonists. Int. J. Mol. Sci. 2018, 19, 2354.
Abstract
Retinoid X receptor (RXR) antagonists are not only useful as chemical tools for biological research, but also are candidate drugs for treatment of various diseases, including diabetes and allergy, although no RXR antagonist has yet been approved for clinical use. In this review, we describe currently available RXR antagonists, their structural classification, and their evaluation, focusing on the latest research.
Keywords
Retinoid X receptor; RXR; antagonists; structural classification; heterodimers; permissive; tRXR
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment